Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Kiniksa Pharmaceuticals International, plc (KNSA)

Kiniksa Names Ross Moat President and Chief Operating Officer, Effective Immediately

Neutral Impact 3 of 5 leadership Written later

Kiniksa Pharmaceuticals appointed Ross Moat as President and Chief Operating Officer, effective immediately, with Mr. Moat continuing to report to Chairman and CEO Sanj K. Patel. Effective January 1, 2027, his base salary and target bonus will rise to $700,000 and 60% from $650,000 and 55%, a change that signals a larger operating role but carries no financial results.

Key points

  • Ross Moat appointed President and Chief Operating Officer on October 17, 2026, effective immediately
  • Mr. Moat has been with the company since June 2019 and most recently served as EVP, Chief Operating Officer
  • Base salary rises to $700,000 from $650,000; target bonus rises to 60% from 55%, both effective January 1, 2027

The filing

CompanyKiniksa Pharmaceuticals International, plc (KNSA)
Form8-K, current report
Filed with the SECOct 22, 2026, 4:28 PM ET
Accession number0001730430-26-000034

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.